Compare Moderna, Inc. (MRNA) vs ProShares Ultra Semiconductors (USD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs ProShares Ultra Semiconductors — how do they compare? Moderna, Inc. trades at $136.69 (market cap $54.14B), while ProShares Ultra Semiconductors trades at $88.3. The key difference: Moderna, Inc. is trading nearer its 52-week high, ProShares Ultra Semiconductors nearer its low. Which is the better fit depends on your goals.
| MRNA | USD | |
|---|---|---|
Market Cap | $54.14B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $174.38 | $113.53 |
52-Week Low | $22.36 | $43.19 |
Enterprise Value | $50.29B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, amid mixed signals. The stock has seen volatility, with a 143% surge over the past month driven by positive cancer vaccine trial results (Fox Business, 2026-09-06), but faces headwinds from declining revenue and persistent net losses. Technical analysis shows a bullish overall signal, with support at $138 and resistance at $145, while fundamentals reveal a challenging profit margin of -142.58% for 2026.
The outlook hinges on pipeline successes, particularly in oncology, but high valuation ratios and competitive pressures pose risks. Analyst consensus is cautious, with a $90.08 price target, reflecting skepticism despite recent clinical milestones. Investors should weigh innovation potential against financial sustainability and market sentiment shifts.
USD stock trades at $89.70, up 1.01% today, with a bullish technical signal from moving averages and neutral oscillators. The company announced a future dividend of $0.14 per share scheduled for June 30, 2026. Recent news highlights include coverage of various US companies' earnings and financial innovations, though specific USD corporate developments are limited in the provided data.
The outlook remains cautiously optimistic given technical strength, but fundamental metrics are unavailable, limiting valuation assessment. Key risks include lack of recent financial data and dependence on broader market sentiment. Investors should await updated earnings reports for clearer fundamental direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About ProShares Ultra Semiconductors
USD is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Dow Jones U.S. Semiconductors™ Index. It is a tactical instrument designed for sophisticated traders looking to magnify short-term bullish views on the U.S. semiconductor industry, specifically focusing on large-cap leaders in the chip and equipment space.
Read more on USD →
